Generic competition · all medicines · read 12 November 2026
Is there a generic of Testosterone Enanthate, and who makes it?
Testosterone Enanthate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 3 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.
Method designed and maintained by Vincent Wesley Couey (ORCID 0009-0005-6869-308X). Data compiled automatically from the Orange Book data files, downloaded 12 November 2026. How these pages are made
- Testosterone Enanthate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 3 generic makers listed as marketed across them.
- 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Injectable, Injection
One to three generic makers listed
Every brand product here is listed as discontinued. 3 generic makers with 3 generic products listed as marketed; the first generic approval is dated 14 June 2006.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Nexus Pharmaceuticals Llc | 14 June 2006 | 1 |
| Hikma Farmaceutica Portugal Sa | 18 September 2012 | 1 |
| Eugia Pharma Specialities Ltd | 28 February 2024 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Solution, Subcutaneous
Brand listed, no generic listed as marketed
Brand listed as marketed: Xyosted (Autoinjector). No generic is listed as marketed.
Patents and exclusivities still listed
- 19 March 2030Patent 11497753 drug product
- 31 July 2031Patent 10279131 drug product
- 21 August 2031Patent 10357609 drug product
- 21 August 2031Patent 10905827 drug product
- 21 August 2031Patent 11446440 drug product
- 4 June 2033Patent 11844804
- 4 June 2033Patent 10821072 drug product
- 11 February 2034Patent 10881798 drug product
8 more patents are listed.
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
What do pharmacies pay for Testosterone Enanthate?
The CMS NADAC survey tracks what pharmacies pay to acquire Testosterone Enanthate: 12 products with year-end prices from 2014 to 2026. See the acquisition cost history on RxGrab. It is a pharmacy cost, not a retail price, and this page does not say how it relates to the number of makers listed above.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.